strong>L'oncologie, la nouvelle priorité de Pierre Fabre</strong>
Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640
Atara Records Net Loss in Quarter - San Fernando Valley Business Journal
EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire
Dans le jardin secret des laboratoires Pierre Fabre
Dans le jardin secret des laboratoires Pierre Fabre
Atara claims first world approval for off-the-shelf T-cell therapy | pharmaphorum
Pierre Fabre, Atara expand licencing for EBV T-cell therapy Ebvallo
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News
Oncologie : Pierre Fabre reprend l'ensemble des droits de l'Ebvallo
Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)
Pierre Fabre | Un groupe pharmaceutique et dermo-cosmétique français
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire
Les Laboratoires Pierre Fabre reçoivent le Prix Galien pour EBVALLO®
Pierre Fabre ponies up $640 to expand T-cell deal with Atara
Atara licenses T cell therapy to Pierre Fabre for up to $640 million
Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy :: Scrip
Les Laboratoires Pierre Fabre accélèrent leur développement dans le domaine de l'onco-hématologie grâce à l'acquisition aux Etats-Unis d'une licence pour une immunothérapie à lymphocytes T
Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online
Atara and Pierre Fabre Collaborate to Commercialize Tabelecleucel for Rare Cancer - Global Genes
Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally
Pierre Fabre and Atara expand licensing agreement for Epstein-Barr therapy
Pierre Fabre Group sur LinkedIn : #oncologie #pierrefabre
Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia
